Full Press Release Details
BridgeBio Pharma's Origin Biosciences Presents New Data On The Natural History Of Molybdenum Cofactor Deficiency (MoCD) Type A At The SSIEM Conference.
BBIO
BridgeBio Pharma's Origin Biosciences Presents New Data On The Natural History Of Molybdenum Cofactor Deficiency (MoCD) Type A At The SSIEM Conference
Key Takeaway: BridgeBio Pharma's Origin Biosciences Presents New Data On The Natural History Of Molybdenum Cofactor Deficiency (MoCD) Type A At The SSIEM Conference
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis